Three novel NY-ESO-1 CD4 T cell epitopes were identified using PBMC obtained from patients who were vaccinated with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein (CHP-NY-ESO-1). The 
Introduction
The NY-ESO-1 antigen was initially identified in esophageal cancer by SEREX and is in the category of cancer/testis (CT) antigens [1] [2] [3] . Its expression is restricted to germ cells in the testis in normal adult tissues, but is also observed in various types of cancer tissue at different frequencies [4] . A characteristic of the NY-ESO-1 antigen is its extremely high immunogenicity. Patients with NY-ESO-1-expressing tumors frequently show a spontaneous immune response to the NY-ESO-1 antigen. An antibody response against the NY-ESO-1 antigen was frequently observed in patients with NY-ESO-1-expressing tumors [5, 6] .
Most patients who showed an antibody response also showed CD4 and CD8 T cell responses [7, 8] . Such strong immunogenicity makes the NY-ESO-1 antigen a very promising candidate target molecule for a cancer vaccine.
Several clinical trials using various preparations of NY-ESO-1 protein vaccine have been reported [3, 9] . The recombinant NY-ESO-1 protein was administered with ISCOMATRIX [10] , cholesterol-bearing hydrophobized pullulan (CHP) [11] , CpG in Montanide [12] , imiquimod [13] or as recombinant vaccinia/fowlpox NY-ESO-1 [14] . Analyses of immune responses in patients vaccinated with the NY-ESO-1 protein showed that integrated immune responses of antibodies, CD4
and CD8 T cells were induced after vaccination.
In this study, we analyzed CD4 T cell responses against NY-ESO-1 in PBMC from 3 patients who were vaccinated with a complex of CHP and NY-ESO-1
protein (CHP-NY-ESO-1) in our clinical trial [11, [15] [16] [17] and determined 3 novel NY-ESO-1 CD4 T cell epitopes. These epitopes were NY-ESO-1 87-100 bound to DRB1*0901, NY-ESO-1 95-107 bound to DQB1*0401 and NY-ESO-1 124-134 bound to DRB1*0803. CD4 T cells used for determining these epitope peptides recognized EBV-B cells or DC that were treated with recombinant NY-ESO-1 protein or NY-ESO-1-expressing tumor cell lysate, suggesting that the epitope peptides are naturally processed. These CD4 T cells showed a cytokine profile with Th1 characteristics.
Materials and Methods

Patients
Patients listed in Fig. 1 were vaccinated with CHP-NY-ESO-1 in our clinical trial reported elsewhere [11, [15] [16] [17] . Patients in the E-series were esophageal cancer patients. Patients in the P-series were prostate cancer patients. M-1
-6 -was a malignant melanoma patient.
Blood samples
Peripheral blood samples were drawn from vaccinated patients after informed consent was obtained. Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation using Histopaque 1077 (Sigma-Aldrich,
St. Louis, MO). CD4 T cells, CD8 T cells, CD14
+ cells and CD19 + cells were purified from PBMC using CD4, CD8, CD14 and CD19 microbeads, respectively, using a large scale column and a magnetic device (Miltenyi Biotec, Auburn, CA).
The residual cells were used as antigen-presenting cells (APC). The cells were stored in liquid N 2 until use. HLA typing of PBMC was performed by a sequence-specific oligo-nucleotide probe and sequence-specific priming of genomic DNA using standard procedures.
Antibodies
Anti-human CD4, anti-human CD8, anti-HLA class I, anti-HLA class II, anti-DQ and anti-DR monoclonal antibodies (mAbs) were purchased from BD Bioscience (San Jose, CA). Anti-DP mAb was purchased from Santa Cruz (Santa Cruz, conjugated goat anti-rabbit IgG was purchased from MBL (Nagoya, Japan).
Cell lines
Epstein-Barr virus-transformed B cells (EBV-B) were generated from CD19 + peripheral blood B cells using the culture supernatant from EBV-producing B95-8 cells. OU-LC-KI and OU-LC-OK were lung adenocarcinoma cell lines established in our laboratory. These cell lines were kept in tissue culture by serial passage and in liquid N 2 .
Peptides
The following 28 18- 
Recombinant proteins
Recombinant NY-ESO-1 [18] and RL-Akt [19] proteins were prepared as described previously. cDNAs for NY-ESO-1 and RL-Akt were cloned into Sph I/Sal I and Bam HI/Sph I sites of the pQE30 vector (Qiagen Science, Valencia, CA), respectively. N-His tagged protein was purified by nickel-ion affinity chromatography under denaturing conditions.
Total RNA isolation and cDNA synthesis
Total RNA was isolated from cell pellets using an RNeasy Mini Kit (QIAGEN, Hilden, Germany). Isolated RNA (2 µg) was reverse transcribed into single-stranded cDNA using Moloney murine leukemia virus reverse transcriptase (Ready-To -Go You-Prime First-Strand Beads, GE Healthcare, Little Chalfont, UK) and oligo (dT) 15 as a primer. cDNA was tested for integrity by amplification of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene.
Reverse transcription (RT)-PCR analysis
To amplify the NY-ESO-1 cDNA segment, primers specific for NY-ESO-1 were designed as described previously [20] . Primers for RT-PCR were: NY-ESO-1
5'-TCCACCACCCTGTTGCTGTA-3' (reverse). The amplification program for NY-ESO-1 was 1 min at 94°C, 1 min at 60°C, and 1.5 min at 72°C for 35 cycles after denaturing at 94°C for 1 min. These cycles were followed by a 10 min elongation step at 72°C. The amplification program for GAPDH was 1 min at 94°C, 1 min at 66°C, and 1.5 min at 72°C for 30 cycles after denaturing at 94°C for 1 min. These cycles were followed by a 10 min elongation step at 72°C. The PCR products were analyzed on a 1.3% agarose gel.
Preparation of monocyte-derived dendritic cells (DC)
CD14 + cells from PBMC were cultured in RPMI medium supplemented with 5% pooled human serum, 10 ng/ml IL-4 and 10 ng/ml granulocyte macrophage colony-stimulating factor (GM-CSF) for 10 days at 37°C in a 5% CO 2 atmospher.
Preparation of tumor cell lysate
Tumor cells (1 x 10   7 ) were subjected to five cycles of rapid freezing in liquid N 2 followed by thawing in a water bath at 37°C.
In vitro stimulation of CD4 T cells
Frozen cells were thawed and re-suspended in AIM-V medium (Invitrogen, Carlsbad, CA) supplemented with 5% pooled human serum (CM), and kept at 37°C in a 5% CO 2 atmosphere for 2 hrs. CD4 T cells (2 x 10 6 ) were stimulated with 28 18-mer overlapping peptides and a 30-mer C-terminal peptide (OLPs) (1 µg/ml for each peptide) spanning the entire NY-ESO-1 using irradiated (40 Gy), autologous CD4-and CD8-depleted PBMC (2 x 10 6 ) as antigen-presenting cells -11 -(APC) in 2 ml of CM supplemented with 20 units/ml rIL-2 (Takeda Chemical Industries, Osaka, Japan) and 10 ng/ml rIL-7 (Peprotech, London, UK) in a 24-well culture plate at 37°C in a 5% CO 2 atmosphere for 12 days. For the second stimulation, 1 x 10 6 instead of 2 x 10 6 responder cells were used in the culture described above.
IFNγ secretion assay
Responder CD4 T cells (1 hrs were also used as APC for stimulation. purified mAb (5 μg/ml) was added to the assay culture.
ELISA
Flow cytometry
EBV-B cells were cultured with rNY-ESO-1 protein, CHP-NY-ESO-1 or
CHP-MAGE at 10 μg/ml of a protein concentration in a 24-well culture plate for 
Tetramer staining
NY-ESO-1 87-100 peptide/HLA-DRB1*0901 tetramer was prepared. The method used was described previously [21] . CD4 T cells were incubated with tetramer for 2 hrs at 37°C in a 5% CO 2 atmosphere. FITC-conjugated anti-CD4 mAb was added at the end of tetramer staining and incubated for an additional 20 min at 4°C. After incubation, the cells were washed twice and analyzed by FACS Calibur.
Confocal microscopy
EBV-B cells were cultured with rNY-ESO-1 protein (10 μg/ml) in a Lab-tek 
Results
Recognition of two dominant peptide regions in NY-ESO-1 by CD4 T cells
NY-ESO-1 124-134 peptide recognition by E-2 CD4 T cells restricted to DRB1*0803
We determined the restriction molecule and the minimal NY-ESO-1 epitope 
NY-ESO-1 95-107 peptide recognition by E-8 CD4 T cells restricted to DQB1*0401
Next, we determined the restriction molecule and minimal epitope in the peptide 91-108 in another dominant region recognized by E-8 CD4 T cells in PBMC obtained after vaccinations ( Fig. 3B and C) . Analysis using a series of truncated peptides as described above suggested that the 13-mer peptide 95-107 was the minimal epitope (Fig. 3D) .
Subdominant CD4 T cell response against NY-ESO-1 87-100 restricted to DRB1*0901 in patient P-4 who showed a dominant response against NY-ESO-1
121-138
We then examined whether there was any subdominant CD4 T cell response in patient P-4, who showed a dominant CD4 T cell response against the peptide 121-138, using the PBMC obtained after vaccinations (Fig. 1) . The dominant response of P-4 CD4 T cells was explained by the presence of DRB1*1502 and *0901 on P-4 cells, both of which were shown to be capable of presenting epitopes derived from the peptide 122-138 [24] .
MACS bead-purified P-4 CD4 T cells were stimulated twice with a mixture of tein, but not control protein (Fig. 7A ). E-2 bulk CD4 T cell recognition of
NY-ESO-1 protein-treated EBV-B cells was blocked by anti-DR and restricted to DRB1*0803 as the recognition of NY-ESO-1 124-134 peptide (data not shown).
We further examined CD4 T cell recognition of tumor cell-derived NY-ESO-1 antigen processed and presented by autologous EBV-B cells, or autologous or HLA class II-matched allogeneic DC using NY-ESO-1-expressing tumor lysates.
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As shown in Fig 7B, E-2 bulk, E-8 A1 and P-4 C3 CD4 T cells all recognized ly-
sate of the NY-ESO-1-expressing lung cancer cell line OU-LC-KI, but not lysate of control OU-LC-OK.
Cytokines secreted from E-2 bulk, E-8 A1 and P-4 C3 CD4 T cells
Cytokines secreted from E-2 bulk, E-8 A1 and P-4 C3 CD4 T cells in stimulation with peptides 121-138, 91-110, and 85-102, respectively, were examined by ELISA. As shown in 
Discussion
In this study, we identified 3 novel NY-ESO-1 CD4 T cell epitopes using PBMC Davis et al. [10] and Nicholaou et al. [33] showed that recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant efficiently induced antibodies, and both CD4 and CD8 T cell responses in malignant melanoma patients. Jäger et al. [14] reported that recombinant vaccinia and fowlpox NY-ESO-1 vaccines preferentially induced a CD8 T cell response. However, Valmori et al. [12] showed that vaccination with NY-ESO-1 protein and CpG in Montanide preferentially induced Analysis was performed using FACS Calibur. 
